Skip to main content
Log in

Treatment of Blepharospasm/Hemifacial Spasm

  • Neurologic Ophthalmology and Otology (RK Shin and DR Gold, Section Editors)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

The treatment of both hemifacial spasm (HFS) and blepharospasm (BEB) requires making the appropriate clinical diagnosis. Advance imaging and electrophysiologic studies are useful; however, one’s clinical suspicion is paramount. The purpose of this review is to summarize current and emerging therapies for both entities. Botulinum toxin (BTX) remains the first-line therapy to treat both conditions. If chemodenervation has failed, surgery may be considered. Due to the risks associated with surgery, the benefits of this option must be carefully weighed. Better surgical outcomes are possible when procedures are performed at tertiary centers with experienced surgeons and advanced imaging techniques. Microvascular decompression is an efficacious method to treat HFS, and myectomy is an option for medication-refractory BEB; the risks of the latter may outweigh any meaningful clinical benefits. Oral agents only provide short-term relief and can cause several unwanted effects; they are reserved for patients who cannot receive BTX and/or surgery. Transcranial magnetic stimulation has gained some traction in the treatment of BEB and may provide safer non-invasive options for refractory patients in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Tan NN. Hemifacial spasm and involuntary facial movements. QJM: monthly journal of the Association of Physicians. 2002;95(8):493.

    Article  PubMed  Google Scholar 

  2. Digre KK. Hemifacial spasm: differential diagnosis, mechanism, and treatment. Adv Neurol. 1988;49:151.

    CAS  PubMed  Google Scholar 

  3. Tan EE. Clinico-radiologic correlation in unilateral and bilateral hemifacial spasm. J Neurol Sci. 2004;222(1–2):59.

    Article  PubMed  Google Scholar 

  4. Miwa HH. Familial hemifacial spasm: report of cases and review of literature. J Neurol Sci. 2002;193(2):97.

    Article  PubMed  Google Scholar 

  5. Han IBI. Supplement. The role of genetic factors in the development of hemifacial spasm: preliminary results. Acta Neurochir. 2008;101:107.

    Article  CAS  Google Scholar 

  6. Yaltho TCT. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord. 2011;26(9):1582.

    Article  PubMed  Google Scholar 

  7. Ohta MM. Does arteriosclerosis contribute to hemifacial spasm? Acta Neurochir. 2016;158(1):181.

    Article  PubMed  Google Scholar 

  8. El Refaee EE. Value of 3-dimensional high-resolution magnetic resonance imaging in detecting the offending vessel in hemifacial spasm: comparison with intraoperative high definition endoscopic visualization. Neurosurgery. 2013;73(1):58.

    Article  PubMed  Google Scholar 

  9. Machado RAR. Intermittent facial spasms as the presenting sign of a recurrent pleomorphic adenoma. World journal of clinical oncology. 2017;8(1):86.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Colosimo CC. A comparative study of primary and secondary hemifacial spasm. Archives of neurology (Chicago). 2006;63(3):441.

    Article  Google Scholar 

  11. Leong JJ. Revisiting the link between hypertension and hemifacial spasm. Sci Rep. 2016;6(1):21082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hohenbleicher HH. Neurovascular contact and blood pressure response in young, healthy, normotensive men. Am J Hypertens. 2002;15(2):119.

    Article  PubMed  Google Scholar 

  13. Chan LLL. Ventrolateral medullary compression in hypertensive patients with hemifacial spasm. Neurology. 2005;65(9):1467.

    Article  CAS  PubMed  Google Scholar 

  14. Boogaarts HDH. Primary hypertension and neurovascular compression: a meta-analysis of magnetic resonance imaging studies. J Neurosurg. 2012;116(1):147.

    Article  PubMed  Google Scholar 

  15. Rudzińska MM. Small volume of the posterior cranial fossa and arterial hypertension are risk factors of hemifacial spasm. Neurol Neurochir Pol. 2014;48(6):383.

    PubMed  Google Scholar 

  16. Edmond ECE. Vascular tortuosity in relationship with hypertension and posterior fossa volume in hemifacial spasm. BMC Neurol. 2016;16(1):120.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yamakami II. Hyperactivity of the facial nucleus produced by chronic electrical stimulation in rats. J Clin Neurosci. 2007;14(5):459.

    Article  PubMed  Google Scholar 

  18. Kameyama SS. Ephaptic transmission is the origin of the abnormal muscle response seen in hemifacial spasm. Clin Neurophysiol. 2016;127(5):2240.

    Article  PubMed  Google Scholar 

  19. Zhong JJ. A clinical analysis on microvascular decompression surgery in a series of 3000 cases. Clin Neurol Neurosurg. 2012;114(7):846.

    Article  PubMed  Google Scholar 

  20. Ying TT. The value of abnormal muscle response monitoring during microvascular decompression surgery for hemifacial spasm. International journal of surgery (London, England). 2011;9(4):347.

    Article  Google Scholar 

  21. Zhou QQ. The role of autonomic nervous system in the pathophysiology of hemifacial spasm. Neurological research (New York). 2012;34(7):643.

    Article  Google Scholar 

  22. Dou NN. The mechanism of hemifacial spasm: a new understanding of the offending artery. Neurological research (New York). 2015;37(2):184.

    Article  Google Scholar 

  23. Wang AA. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998;21(12):1740.

    Article  CAS  PubMed  Google Scholar 

  24. Tan EE. Behind the facial twitch: depressive symptoms in hemifacial spasm. Parkinsonism Relat Disord. 2005;11(4):241.

    Article  PubMed  Google Scholar 

  25. Han II. Unusual causes and presentations of hemifacial spasm. Neurosurgery. 2009;65(1):130.

    Article  PubMed  Google Scholar 

  26. Schwarze HPH. Oculostapedial synkinesis. Otolaryngol Head Neck Surg. 1995;113(6):802.

    Article  CAS  PubMed  Google Scholar 

  27. Evinger CC. Animal models for investigating benign essential blepharospasm. Curr Neuropharmacol. 2013;11(1):53.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Defazio GG. Blepharospasm 40 years later. Mov Disord. 2017;32(4):498.

    Article  PubMed  Google Scholar 

  29. Digre KBK. Benign essential blepharospasm—there is more to it than just blinking. J Neuroophthalmol. 2015;35(4):379.

    Article  PubMed  Google Scholar 

  30. Grandas FF. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51(6):767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Defazio GG. A family study on primary blepharospasm. J Neurol Neurosurg Psychiatry. 2006;77(2):252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Steeves TDT. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012;27(14):1789.

    Article  PubMed  Google Scholar 

  33. Defazio GG. Development and validation of a clinical guideline for diagnosing blepharospasm. Neurology. 2013;81(3):236.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Rana AA. Prevalence of blepharospasm and apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential tremor. Eur Neurol. 2012;68(5):318.

    Article  PubMed  Google Scholar 

  35. Peckham ELE. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol. 2011;18(3):382.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Martino DD. Menopause and menarche in patients with primary blepharospasm: an exploratory case-control study. Eur Neurol. 2002;47(3):161.

    Article  PubMed  Google Scholar 

  37. Evinger CC. Benign essential blepharospasm is a disorder of neuroplasticity: lessons from animal models. J Neuroophthalmol. 2015;35(4):374.

    Article  PubMed  Google Scholar 

  38. Lee JJ. Natural history of untreated hemifacial spasm: a study of 104 consecutive patients over 5 years. Stereotact Funct Neurosurg. 2017;95(1):21.

    Article  PubMed  Google Scholar 

  39. • DAD P. A dynamic circuit hypothesis for the pathogenesis of blepharospasm. Front Comput Neurosci. 2017;11:11. This paper proposes a new model for the pathophysiology of BEB, which may serve as a tool for implementing future therapeutic options.

    Google Scholar 

  40. Yang JJ. Altered regional spontaneous neuronal activity in blepharospasm: a resting state fMRI study. J Neurol. 2013;260(11):2754.

    Article  PubMed  Google Scholar 

  41. Martino DD. The phenomenology of the geste antagoniste in primary blepharospasm and cervical dystonia. Mov Disord. 2010;25(4):407.

    Article  PubMed  Google Scholar 

  42. Valls-Sole JJ. Blepharospasm: update on epidemiology, clinical aspects, and pathophysiology. Front Neurol. 2016;7:45.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Conte AA. Is increased blinking a form of blepharospasm? Neurology. 2013;80(24):2236.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Lamberti PP. Frequency of apraxia of eyelid opening in the general population and in patients with extrapyramidal disorders. Neurol Sci. 2002;23(Suppl 2):s81.

    Article  PubMed  Google Scholar 

  45. Weiss EME. Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord. 2006;21(8):1175.

    Article  PubMed  Google Scholar 

  46. •• Defazio GG. Development and validation of a clinical scale for rating the severity of blepharospasm. Mov Disord. 2015;30(4):525. This paper discusses the nuances of a more comprehensive clinical scale that better addresses BEB by taking into consideration the natural history of the disease.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Conte AA. Non-motor symptoms in patients with adult-onset focal dystonia: sensory and psychiatric disturbances. Parkinsonism Relat Disord. 2016;22(Suppl 1):S111.

    Article  PubMed  Google Scholar 

  48. Avanzino LL. Quality of sleep in primary focal dystonia: a case-control study. Eur J Neurol. 2010;17(4):576.

    Article  CAS  PubMed  Google Scholar 

  49. Romano RR. Impaired cognitive functions in adult-onset primary cranial cervical dystonia. Parkinsonism Relat Disord. 2014;20(2):162.

    Article  PubMed  Google Scholar 

  50. Sandyk RR. Baclofen in hemifacial spasm. Int J Neurosci. 1987;33(3–4):26.

    Google Scholar 

  51. Alexander GEG. Carbamazepine for hemifacial spasm. Neurology. 1982;32(3):286.

    Article  CAS  PubMed  Google Scholar 

  52. Herzberg LL. Management of hemifacial spasm with clonazepam. Neurology. 1985;35(11):1676.

    Article  CAS  PubMed  Google Scholar 

  53. Daniele OO. Gabapentin in the treatment of hemifacial spasm. Acta Neurol Scand. 2001;104(2):110.

    Article  CAS  PubMed  Google Scholar 

  54. Bandini FF. Gabapentin as treatment for hemifacial spasm. Eur Neurol. 1999;42(1):49.

    Article  CAS  PubMed  Google Scholar 

  55. Patel JJ. Gabapentin for the treatment of hemifacial spasm. Clin Neuropharmacol. 1996;19(2):185.

    Article  CAS  PubMed  Google Scholar 

  56. Deleu DD. Levetiracetam in the treatment of idiopathic hemifacial spasm. Neurology. 2004;62(11):2134.

    Article  PubMed  Google Scholar 

  57. Biagio Carrieri PP. Efficacy of levetiracetam in hemifacial spasm: a case report. Clin Neuropharmacol. 2008;31(3):187.

    Article  PubMed  Google Scholar 

  58. Siniscalchi AA. Idiopathic hemifacial spasm responsive to zonisamide: a case report. Clin Neuropharmacol. 2009;32(4):230.

    Article  PubMed  Google Scholar 

  59. Kuroda TT. Efficacy of levetiracetam in primary hemifacial spasm. J Clin Neurosci. 2016;34:213.

    Article  CAS  PubMed  Google Scholar 

  60. Vijayakumar DD. Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017;372:57.

    Article  CAS  PubMed  Google Scholar 

  61. Gollomp SMS. Therapeutic trials in Meige syndrome. Adv Neurol. 1983;37:207.

    CAS  PubMed  Google Scholar 

  62. Nutt JGJ. Cranial dystonia: double-blind crossover study of anticholinergics. Neurology. 1984;34(2):215.

    Article  CAS  PubMed  Google Scholar 

  63. Merikangas JRJ. Blepharospasm: successful treatment with clonazepam. Ann Neurol. 1979;5(4):401.

    Article  CAS  PubMed  Google Scholar 

  64. Ohara SS. Mexiletine in the treatment of blepharospasm: experience with the first three patients. Mov Disord. 1999;14(1):173.

    Article  CAS  PubMed  Google Scholar 

  65. Jankovic JJ. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11(1):41.

    Article  CAS  PubMed  Google Scholar 

  66. •• ARA B. Retrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci. 2012;33(2):261. This retrospective analysis thoroughly evaluates the factors that limit the determination of a true dose equivalent between ONA and ABO in the treatment of both BEB and HFS.

    Article  Google Scholar 

  67. Broadbent TJT. A survey of current blepharospasm treatment patterns among oculoplastic surgeons. Ophthal Plast Reconstr Surg. 2016;32(1):24.

    Article  PubMed  Google Scholar 

  68. •• DMD S. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699. This paper provides the most recent clinical recommendations made by the AAN regarding the use of BTX injections in the treatment of HFS.

    Article  Google Scholar 

  69. Hallett MM. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon (Oxford). 2013;67:94.

    Article  CAS  Google Scholar 

  70. •• DMD S. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818. This paper provides the most recent clinical recommendations made by the AAN regarding the use of BTX injections in the treatment of BEB.

    Article  CAS  Google Scholar 

  71. Martinez-Ramirez DD. Comparable botulinum toxin outcomes between primary and secondary blepharospasm: a retrospective analysis. Tremor and other hyperkinetic movements (New York, NY). 2014;4:286.

    Google Scholar 

  72. Rosenstengel CC. Hemifacial spasm: conservative and surgical treatment options. Dtsch Arztebl Int. 2012;109(41):667.

    PubMed  PubMed Central  Google Scholar 

  73. Hanganu AA. Grey matter microstructural integrity alterations in blepharospasm are partially reversed by botulinum neurotoxin therapy. Public library of science. PLoS One. 2016;11:e0168652.

    Article  CAS  Google Scholar 

  74. Quartarone AA. Enhanced long-term potentiation-like plasticity of the trigeminal blink reflex circuit in blepharospasm. J Neurosci. 2006;26(2):716.

    Article  CAS  PubMed  Google Scholar 

  75. Sampaio CC. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1. Mov Disord. 1997;12(6):1013.

    Article  CAS  PubMed  Google Scholar 

  76. Fernandez HHH. Observational study of incobotulinumtoxinA for cervical dystonia or blepharospasm (XCiDaBLE): interim results for the first 170 subjects with blepharospasm. Tremor and other hyperkinetic movements (New York, N.Y.). 2014;4:238.

    Google Scholar 

  77. Kongsengdao SS. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study. J Med Assoc Thail. 2012;95(Suppl 3):S48.

    Google Scholar 

  78. Karp BIB. Botulinum toxin treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol. 2016;36(1):84.

    Article  PubMed  Google Scholar 

  79. Kollewe KK. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. Journal of neural transmission (Vienna, Austria : 1996). 2010;117(6):759.

    Article  Google Scholar 

  80. Cakmur RR. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol. 2002;249(1):64.

    Article  CAS  PubMed  Google Scholar 

  81. Choe WJW. Increasing the area and varying the dosage of botulinum toxin a injections for effective treatment of hemifacial spasm. Acta Otolaryngol. 2016;136(9):952.

    Article  CAS  PubMed  Google Scholar 

  82. •• Kollewe KK. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®. Journal of neural transmission (Vienna, Austria : 1996). 2015;122(3):427. One of the first and largest long-term studies comparing the different formulations of BTX in the treatment of BEB. The study also validated the increase efficacy of using shorter inter-injection periods.

    Article  CAS  Google Scholar 

  83. Dutton JJJ. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007;52(1):13.

    Article  PubMed  Google Scholar 

  84. Batisti JPMJ. Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated. Arq Neuropsiquiatr. 2017;75(2):87.

    Article  PubMed  Google Scholar 

  85. Ababneh OHO. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clinical & experimental ophthalmology. 2014;42(3):254.

    Article  Google Scholar 

  86. Truong DDD. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm. Journal of neural transmission (Vienna, Austria : 1996). 2013;120(9):1345.

    Article  CAS  Google Scholar 

  87. Ojo OOO. Is it time for flexibility in botulinum inter-injection intervals? Toxicon (Oxford). 2015;107(pt a):72.

    Article  CAS  Google Scholar 

  88. Fezza JJ. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm. J Neurol Sci. 2016;367:56.

    Article  CAS  PubMed  Google Scholar 

  89. •• MHM S. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years. J Clin Neurosci. 2015;22(8):1319. This retrospective analysis provides valuable data on the treatment of HFS with BTX, including validation of the preferred injection site.

    Article  CAS  Google Scholar 

  90. Xiao LL. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment. Neurol Sci. 2016;37(11):1807.

    Article  PubMed  Google Scholar 

  91. Atassi MZM. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S68.

    Article  PubMed  Google Scholar 

  92. Bihari KK. Safety, effectiveness, and duration of effect of Botox after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin. 2005;21(3):433.

    Article  CAS  PubMed  Google Scholar 

  93. Chundury RVR. Subjective and objective measures in the treatment of hemifacial spasm with onabotulinumtoxinA. Ophthal Plast Reconstr Surg. 2016;32(2):133.

    Article  PubMed  Google Scholar 

  94. Wirtschafter JDJ. Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm. Ophthalmology (Rochester, Minn). 1998;105(2):342.

    Article  CAS  Google Scholar 

  95. Sekula RFR. Microvascular decompression for hemifacial spasm in patients >65 years of age: an analysis of outcomes and complications. Muscle Nerve. 2013;48(5):770.

    Article  PubMed  Google Scholar 

  96. Miller LEL. Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review. Br J Neurosurg. 2012;26(4):438.

    Article  PubMed  Google Scholar 

  97. •• Sharma RR. Microvascular decompression for hemifacial spasm: a systematic review of vascular pathology, long term treatment efficacy and safety. Neurol India. 2017;65(3):493. The largest meta-analysis studying the long-term clinical utility of MVD in HFS patients. The review provides the best analysis of complication rates from the procedure. It also identifies the AICA as the most common offending vessel.

    Article  PubMed  Google Scholar 

  98. Ohta MM. Preoperative assessment of hemifacial spasm by the coronal heavily T2-weighted MR cisternography. Acta Neurochir. 2014;156(3):565.

    Article  PubMed  Google Scholar 

  99. Jia JJ. Preoperative evaluation of patients with hemifacial spasm by three-dimensional time-of-flight (3D-TOF) and three-dimensional constructive interference in steady state (3D-CISS) sequence. Clin Neuroradiol. 2016;26(4):431.

    Article  PubMed  Google Scholar 

  100. Fukunaga AA. A recommendation on the basis of long-term follow-up results of our microvascular decompression operation for hemifacial spasm. Acta Neurochir. 2013;155(9):1693.

    Article  PubMed  Google Scholar 

  101. Nagata YY. The “multi-scope technique” for microvascular decompression. World neurosurgery. 2017;103:310.

    Article  PubMed  Google Scholar 

  102. Ishikawa MM. Microvascular decompression under neuroendoscopic view in hemifacial spasm: rostral-type compression and perforator-type compression. Acta Neurochir. 2015;157(2):329.

    Article  PubMed  Google Scholar 

  103. Thirumala PDP. Part B, skull base: brainstem auditory evoked potentials’ diagnostic accuracy for hearing loss: systematic review and meta-analysis. Journal of neurological surgery. 2017;78(1):43.

    Article  PubMed  Google Scholar 

  104. Liu MXM. The significance of abnormal muscle response monitoring during microvascular decompression for hemifacial spasm. Acta Neurochir Suppl. 2017;124:297.

  105. Huang CC. An optimized abnormal muscle response recording method for intraoperative monitoring of hemifacial spasm and its long-term prognostic value. International journal of surgery (London, England). 2017;38:67.

    Article  Google Scholar 

  106. El Damaty AA. The value of lateral spread response monitoring in predicting the clinical outcome after microvascular decompression in hemifacial spasm: a prospective study on 100 patients. Neurosurg Rev. 2016;39(3):455.

    Article  PubMed  Google Scholar 

  107. Sun HH. The strategy of microvascular decompression for hemifacial spasm: how to decide the endpoint of an MVD surgery. Acta Neurochir. 2014;156(6):1155.

    Article  PubMed  Google Scholar 

  108. Kim CC. The potential value of the disappearance of the lateral spread response during microvascular decompression for predicting the clinical outcome of hemifacial spasms: a prospective study. Neurosurgery. 2010;67(6):158.

    Google Scholar 

  109. Patel BCKB. Surgical management of essential blepharospasm. Otolaryngol Clin N Am. 2005;38(5):1075.

    Article  Google Scholar 

  110. Pariseau BB. Myectomy for blepharospasm 2013. Curr Opin Ophthalmol. 2013;24(5):488.

    PubMed  Google Scholar 

  111. Georgescu DD. Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening. Am J Ophthalmol. 2008;145(3):541.

    Article  PubMed  Google Scholar 

  112. Kent TLT. Effect of upper eyelid myectomy on subsequent chemodenervation in the management of benign essential blepharospasm. Ophthal Plast Reconstr Surg. 2015;31(3):222.

    Article  PubMed  Google Scholar 

  113. Reese RR. Long-term clinical outcome in Meige syndrome treated with internal pallidum deep brain stimulation. Mov Disord. 2011;26(4):691.

    Article  PubMed  Google Scholar 

  114. Yamada K. Pallidal stimulation for medically intractable blepharospasm. BMJ Case Rep. 2016. https://doi.org/10.1136/bcr-2015-214241.

  115. • Kranz GG. Transcranial magnetic brain stimulation modulates blepharospasm: a randomized controlled study. Neurology. 2010;75(16):1465. The study provides class II evidence that rTMS provides a safe and efficacious option for the treatment of BEB

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kemar E. Green DO.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Neurologic Ophthalmology and Otology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Green, K.E., Rastall, D. & Eggenberger, E. Treatment of Blepharospasm/Hemifacial Spasm. Curr Treat Options Neurol 19, 41 (2017). https://doi.org/10.1007/s11940-017-0475-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-017-0475-0

Keywords

Navigation